AKT1 and glioma: Targeting the PI3-kinase-Akt-mTOR signaling pathway with the mTOR small molecule inhibitor everolimus has also shown promising efficacy in a phase II clinical trial for children with recurrent/progressive NF1-associated low-grade gliomas [30].